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ABSTRACT: Introduction: hepatic cirrhosis (HC) is a disease with 
high morbidity and mortality in Brazil. Its treatment is complex 
and requires from lifestyle changes to large surgeries such as liver 
transplantation. To reach the best treatment results, it is necessary 
to guarantee a good patient’s adherence to the treatment. Studies 
indicate that the patient’s self-knowledge about his or her clinical 
condition is a determining factor in its adherence. Objectives: to 
assist in the design of an instrument that evaluates knowledge about 
the disease and treatment of HC. Methodology: The development 
process of the instrument will be divided into 3 stages: construction 
of the instrument (1st stage), evaluation of content validity and clarity 
of the instrument (2nd stage) and assessment of the reliability of 
the instrument (3 rd stage). Results: an instrument to evaluate the 
cirrhotic patient knowledge about the disease was made, analyzed 
by specialists and approved in the criteria proposed. Conclusions: 1) 
The development of the instrument followed the steps described in 
literature. 2) The suggestion of the evaluators allowed to restructure 
the questions making them clearer and more relevant to the proposal 
of the instrument. 3) it was possible to achieve satisfactorily the 
proposal of the construction of the instrument. 
Keywords: Liver cirrhosis; Self concept; Surveys and questionnaires; 
Health education.
RESUMO: Introdução: cirrose hepática (CH) é uma doença com 
alta morbidade e mortalidade no Brasil. Seu tratamento é complexo 
e requer desde mudanças no estilo de vida até se submeter a grandes 
cirurgias, como o transplante hepático. Para alcançar os melhores 
resultados é necessário que o paciente tenha uma boa aderência ao 
tratamento. Estudos indicam que o conhecimento do paciente sobre 
sua condição clínica é um fator determinante na aderência. Objetivos: 
criar um instrumento que meça o conhecimento que um paciente 
com CH tem sobre sua doença e seu tratamento. Methodologia: 
o processo de desenvolvimento do instrument foi dividido em 3 
estágios: construção do instrument (1º estágio), avaliação do conteúdo 
e claridade do instrument (2º estágio) e avaliação da confiabilidade 
do instrument (3º estágio). Results: um instrument para avaliar 
o conhecimento do paciente cirrótico sobre sua doença foi feito, 
analisado por especialistas e aprovado pelos critérios propostos. 
Conclusions: 1) O desenvolvimento do instrumento seguiu os passos 
descritos na literatura. 2) As sugestões dos avaliadores foram seguidas 
na reestruturação das questões, tornando-as mais claras e relevantes 
para a proposta do instrumento. 3) Foi possível alcançar de forma 
satisfatória a proposta de construção do instrumento. 
Descritores: Cirrose hepática; Autoimagem; Inquéritos e 
questionários; Educação em saúde. 
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INTRODUCTION
Hepatic Cirrhosis
Hepatic Cirrhosis (HC) is a disease characterized by different mechanisms that result in the 
formation of irreversible scars in the liver, making it harder 
for the organ to perform its normal functions. The main 
etiological factors are alcohol abuse, viral hepatitis and 
autoimmune diseases. In the last decade, there has been an 
increase of cases related to cryptogenic liver disease and 
non-alcoholic fatty liver disease1,2. 
In 2013, HC was the 13th major cause of death in the 
world, responsible for approximately 1 million deaths (2). In 
Brazil, there were 853,751 hospital admissions attributed 
to CH in the period 2001 and 2010. Of the total deaths 
in the country in this same time frame, CH corresponds 
to the 8th leading cause of death in the country. Despite 
the importance of CH in Brazil, there isn’t more precise 
epidemiological data regarding this condition3,4.  
The disease initially is characterized by an 
asymptomatic phase, followed by a symptomatic phase 
marked by the development of symptoms such as: ascites, 
jaundice, fatigue, pruritus, gastrointestinal hemorrhage, 
esophageal varices and portal hypertension (5). With the 
worsening of liver functions, the appearance of these 
symptoms may accelerate the development of other 
complications such as renal worsening, hepatopulmonary 
syndrome and sepsis6,7. The complex drug treatment 
although not curative at all may contribute to symptom 
relief and control of CH complications8. 
HC may progress to acute or chronic hepatic 
impairment, and in these cases the option of treatment 
is liver transplantation. Brazil is the country that most 
transplants in Latin America, occupying the third place in 
the world. Between 2005 and 2015, 14,817 liver transplants 
were performed in Brazil9,10.. According to data published 
by the Brazilian Association of Organ Transplantation 
(ABTO), in 2016 the country had 62 active staff and 
performed a total of 1880 transplants of liver. Presenting 
a list of 1331 active patients waiting for transplantation11.
Because it is a chronic disease, HC requires changes 
in the habits of the patient. Human behavior are shaped 
by the beliefs of each individual, these which will directly 
influence the decisions of the patient to follow the treatment 
or not. Beliefs are derived from different sources such as 
personal, family, social experiences12.
In this perspective, knowledge is one of the 
variables that will lead to a change in behavior towards 
illness, in addition to the time of diagnosis, family support, 
beliefs related to health and illness, among others, will 
also contribute to the management of the patient in the 
face of illness13. In the case of patients who require solid 
organ transplantation, the need for an educational process 
becomes even more relevant. In this case, the patient must 
learn how to administer the new medication that will be 
used for the rest of his life, in addition to adhering to 
changes in lifestyle14. 
In view of the above, it is essential for the health 
professional to conceive the transmission of information 
as a relevant point of their work with the patient. Develop 
ways to make information accessible to the population in 
which it is being served. Low levels of schooling - poor 
patient literacy, for example, can interfere negatively 
with the prognosis of the disease, as the understanding of 
medical guidance is impaired, thereby increasing mortality 
rates, visits to emergency centers and readmissions15.  
Thus, entering the population of the present study 
- the patients with HC and the importance of the health 
team to take into account the information transmitted, 
it is possible to mention a research developed with the 
objective of evaluating the patients’ knowledge about the 
process of liver transplantation. The results demonstrate 
the difficulty that the teams encounter in communicating 
with the patient. The research was carried out with 62 
candidates on a transplant list, with a mean score of 7.4 with 
a standard deviation of 2.5. Post-transplantation questions 
had the worst hit rates, 43% reported receiving information, 
and 77.4% did not think it was sufficient. Regarding the 
understanding of the disease and transplantation, 37.1% and 
45.2%, respectively, indicated insufficient understanding. 
Based on these results, the need to develop educational 
strategies capable of improving the understanding of the 
transplantation process is emphasized16.
As a basis for the studies cited for a good prognosis 
of treatment the patient needs to know his / her illness 
and the implications involved treatment. One strategy for 
accessing the patient’s knowledge is through measuring 
instruments. 
Some studies have developed and validated 
instruments aimed at understanding the patient’s knowledge 
of his disease. In the national scope we can mention 
Padilha et al.17 who investigated beliefs and attitudes in 
valvopathic patients. The work of Bonin et al.18, constructed 
a questionnaire to measure the knowledge of the patient 
with heart failure. The research of Zulianello et al.19, who 
constructed and validated a psychometric scale to assess 
the knowledge of hypertensive patients. Maciel et al.20 
developed a belief scale on mental illness. In addition, 
referring to international studies, we have Benhamou 
et al (14) who developed and validated an instrument to 
evaluate fears and beliefs in patients with osteoarthritis 
of the knee. Siklosi et al.21 who developed and validated a 
questionnaire to evaluate patients’ knowledge about Cystic 
Fibrosis. Bardazzi et al.21 validaram um questionário sobre 
a consciência dos pacientes com psoríase. Zschocke et al.23 
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validated a questionnaire on the conscience of patients 
with psoriasis. Zschocke et al.24 developed an instrument 
to evaluate the quality of life in patients with primary 
hyperparathyroidism. 
The aforementioned researches had as objective 
the development of instruments aiming at a better 
understanding of the patient about his illness.
Construction of research instruments 
The stages of construction of a measuring instrument 
can be presented as follows:
1st step – definition of the objectives of the 
instrument28;
2nd step –  construction of items and response scales: 
items should not be chosen at random. The search in the 
literature, in national and international databases is the 
main resource used in the development of measurement 
instruments. Besides the construction of the items another 
relevant point is the choice of the method to obtain answers. 
The “likert scale” is the most used to survey opinions, 
attitudes and evaluations25,26; 
3rd step – selection and organization of items: 
items should be organized in a logical manner to reduce 
the mental effort of the individual. The construction of 
a questionnaire should be formulated in such a way as 
to present questions respecting the principles of clarity, 
coherence and neutrality. The writing of the questions 
should use clear and comprehensible language, avoiding 
complex, ambiguous and too long questions25,27. 
After having organized and structured the items 
the instrument needs to be tested for the hypothesis that 
the defined items adequately represent the domains of 
the construct. The procedure of choice for this purpose 
is content evaluation. The validity of content is a 
fundamental process in the development of an instrument. 
It is not represented statistically, which means that it is not 
expressed by a correlation coefficient but results from the 
judgment of different examining specialists. Because it is a 
subjective method, it is necessary to use other psychometric 
measures28,29.   
Still at this stage it is recommended that a 
quantitative analysis be done between the agreement of 
the evaluating (specialists) members. One way to perform 
this analysis is through the Content Validity Index (CVI). 
The CVI indices measure the proportion of experts who 
are in agreement on the items of the instrument. Allows 
you to analyze each item individually and subsequently 
the instrument as a whole. It is a widely used method in 
the health area28,30,31.
4th – Pre-test: the objective is to evaluate whether all 
items are comprehensible to all members of the population 
to which the instrument is intended. At the end of this step 
the measuring instrument is ready to have its psychometric 
properties evaluated25. 
MATERIAL AND METHOD
It is a cross-sectional study, which will include 
intentional and non-probablistic sample t.
The study was submitted to the “Comitê de Ética em 
Pesquisa da Instituição” (CAPPESQ), approved according 
to Research Protocol no. 15056. After approval, the process 
of development was divided into five stages, as following.
Steps of the development process of the instrument
Step 1: Construction of the instrument
The construction of the instrument was carried out 
based on an extensive bibliographical review, with relevant 
publications on the subject in the last 5 years. 
The instrument was divided into 4: signs and 
symptoms, diagnosis, treatment and medication. The first 
version of the instrument had 15 questions in each of 
the topics, presenting a total of 60 questions. There is no 
consensus on the number of items that should contain a 
scale, however some authors point out that it is advisable 
for each dimension (category) to have between five and 
ten items33. 
Step 2: Instrument evaluation process
A group of professionals was invited to participate 
in the evaluation process of the instrument, to verify 
the validity of the content. The requirement used in the 
selection of the specialists was: to act for at least 1 year 
with assistance from CH patients. At that stage, 5 health 
professionals from different areas (a nurse, a doctor, two 
psychologists and a social worker) participated in the 
evaluation process. 
Criteria for instrument evaluation: content validity 
Content validity is defined as a measure that 
evaluates whether the test (instrument) measures what it is 
intended to measure. That is, validity refers to an index of 
agreement between what it measures and what it proposes 
to measure34. 
Quantitative Analysis: the content validity index 
(CVI) was the tool used.  The calculation in this method is 
done through a “likert scale” of 4 ordinal points. According 
to the authors for the evaluation of the relevance of the item 
(question) the experts can choose 1- not clear, 2-unclear, 
3-quite clear, 4-very clear. The index score is calculated 
from the sum of items that have been marked by experts 
as “3” or “4”, dividing that sum by the total number of 
responses. Items that received 1 or 2 should be reviewed 
or deleted28. 
The formula for evaluating each item can be 
described as follows:  
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CVI= (Number of responses “3’ or “4”) / (Total number of 
responses)
In this paper, it is emphasized that the “likert scale” 
used was 10 ordinal points. For each question, a scale 
was organized with values ranging from 1 to 10, with 1 
to 4 being the question considered confusing, 5 to 7, the 
question is considered unclear, 8 to 10 the question is 
considered clear. It is possible to describe the IVC formula 
for the work as follows:
CVI= (Number of responses “8”, “9” or “10”) / (Total number 
of responses)
It is important to note that even with the variation 
of the “likert scale” in this work, there was no statistical 
change in the result of the evaluation of each item. The 
minimum agreement rate to maintain the question remains 
the same as described in the literature which indicates a 
minimum acceptable agreement of 0.8024,30. The result 
obtained from the CVI formula should be a value equal to 
or greater than 0.80 to maintain the question.
For each of the questions the response of each 
evaluator is evaluated. Responses with scores equal to or 
greater than 8 are retained. Responses with a value less 
than 8 are discarded. The final score of the question is the 
number of valid answers (8.9 or 10 - clear question) divided 
by the total number of answers and multiplied by 100.
Qualitative Analysis: at the end of each question 
a space was left for the evaluators to make suggestions 
regarding the analysis of content, clarity and semantics of 
the question. The experts were able to assess the quality 
of the items, whether the questions were clear and whether 
the content was understandable.
Step 3: Restructuring of the instrument
The statistical results of the quantitative analysis 
added to the qualitative analysis generated the second 
version of the instrument. Some questions were discarded 
because they did not meet the established criteria, 
other questions were reworked and new questions were 
developed and included in the instrument. All changes were 
based on expert considerations.
The second version of the instrument presented 
46 questions, the topics (signs and symptoms, diagnosis, 
treatment and medication) were kept. In the second version 
the drugs entered as a subtopic of the treatment category. 
It was decided to reduce the number of questions of all 
categories. Thus, each topic got 10 questions and the 
subtopics drugs with 6 questions. 
Step 4: Instrument reassessment process
After the construction of the second version of the 
instrument, the experts who participated in the first round 
were contacted (via email) to participate again in the 
evaluation. After accepting, the second printed version of 
the instrument was delivered. At this stage, experts were 
asked to complete a form with their data and professional 
experiences. 
The evaluation process, in this second stage was 
simpler. The questions that were re-elaborated passed 
only by quantitative analysis, using the same method - the 
Content Validity Index (CVI). In addition, the second 
version of the instrument had another “likert scale” (of 5 
points) for quantitative analysis. 
The new questions that were included, besides going 
through the quantitative analysis process described above, 
also had a space for suggestions and comments (semantic 
analysis).  
Step 5: Development of the final version of the 
instrument
 At the end of the second round, the corrections were 
considered appropriate. The questions of the instrument 
went through the steps proposed by the literature making 
the instrument adequate and reliable. The questions have 
undergone semantic changes according to the experts’ 
suggestion, reaching scores equal to or greater than 8.
The questions developed in this process will 
subsequently be transformed into an instrument used as 
a questionnaire with patients. There are different ways 
to build a quiz, they can be open, closed or mixed. In the 
present study, we opted for the development of a closed 
questionnaire, seeking the practicality, ease and speed of 
responses. The proposal is that the questionnaire becomes 
a possible tool to be used by different health professionals 
(doctors, nurses, psychologists, among others) who work 
in the care of CH patients. 
The questions of the instrument that will be used 
with the patients will be measured through a “likert scale” 
of 5 points. The patient may choose an alternative response. 
The alternatives will be: totally disagree, partially disagree, 
do not know answer, partially agree, totally agree. The 
number of odd response alternatives allows one to place a 
neutral point in the middle of the scale26. 
RESULTS AND STATISTICAL ANALYSIS 
First version of the instrument
From the bibliographic review, 60 questions were 
constructed, as mentioned the questions were divided into 
blocks following the topics (signs and symptoms, diagnosis, 
treatment, medication). Each topic has 15 questions.
Experts analyzed each question individually using 
a 10-point “likert scale” to evaluate each question. The 
options of evaluation were: confusing question, question 
considered unclear, question considered clear. In addition, 
at the end of each question was a space for suggestions 
and comments.
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Evaluation of psychometric properties
The results of the questions are described in the 
Tables 1- signs and symptoms, 2 - diagnosis, 3 - treatment, 
4 medicines. For each topic we developed 15 questions, 
the evaluation was done by 5 experts, which resulted in a 
total of 75 responses (15 x 5 = 75) per topic.
When evaluating the whole instrument including the 
75 responses of each topic, which leads to a total of 300 
responses, a total of 12% of answers considered confusing 
(36/300), 17.7% of answers considered little (53/300) and 
70.3% of responses considered clear (211/300). 
Two tables by topics will be presented below. The 
first refers to the questions of the instrument and the second 
to the results of the expert evaluation
Table 1 – Signs and symptons: Questions presentation
SIGNS AND SYMPTONS
Q1 Symptoms of liver cirrhosis are cured by changing lifestyle habits
Q2 Having no symptoms means that liver cirrhosis is not considered severe
Q3 Body itching, yellowing, ascites and encephalopathy are some symptoms of liver cirrhosis
Q4 Liver cirrhosis may cause malnutrition, leaving the patient weak
Q5 Patients may have a diagnosis of cirrhosis and have no symptoms, ie have the disease compensated
Q6 Ascites is a common complication of cirrhosis and is characterized by the retention of fluid in the belly
Q7
Hepatic cirrhosis, in some cases, presents complications 
(esophageal varices, encephalopathy, ascites) that should 
be treated as they may complicate further health status
Q8
Following the nutritionist’s dietary guidelines may aid in 
the control of ascites and encephalopathy, complications 
common in liver cirrhosis
Q9
Hepatic encephalopathy present as symptoms: mental 
confusion, disorientation, tremors in the hands, slurred 
speech, slow movement, and in more severe cases can 
lead to coma
Q10 Liver cirrhosis may trigger symptoms of anxiety and depression
Q11 Hepatic encephalopathy can affect your ability to work and drive and can cause car accident risks.
Q12
When presenting symptoms of jaundice, that is the 
yellowish, it means that the liver is regenerating and 
showing signs of improvement
Q13 Patients with hepatic encephalopathy should be monitored on leaving home.
Q14 The liver with cirrhosis releases toxic substances that can attack the cardiovascular system causing cardiac arrest
Q15
The patient presenting with a hepatic encephalopathy crisis 
should seek help considering that the condition may worsen 
rapidly and become an emergency condition
Table 2 – Signs and symptons: Validation of content. According 
to experts’ in the topic Signs and Symptoms presented as answers: 
5.3% considered confusing (4/75), 16% considered unclear 
(12/75) and 78.7% (59/75) considered clear
SIGNS AND SYMPTONS
 
Confusing 
(0, 1, 2, 3, 4)
Unclear  
(5, 6, 7)
Clear  
(8, 9, 10)
N (%) N (%) N (%)
Q1 0 (0%) 2 (40%) 3 (60%)
Q2 0 (0%) 0 (0%) 5 (100%)
Q3 0 (0%) 1 (20%) 4 (80%)
Q4 0 (0%) 0 (0%) 5 (100%)
Q5 0 (0%) 2 (40%) 3 (60%)
Q6 0 (0%) 1 (20%) 4 (80%)
Q7 0 (0%) 1 (20%) 4 (80%)
Q8 0 (0%) 2 (40%) 3 (60%)
Q9 0 (0%) 0 (0%) 5 (100%)
Q10 0 (0%) 2 (40%) 3 (60%)
Q11 1 (20%) 0 (0%) 4 (80%)
Q12 2 (40%) 0 (0%) 3 (60%)
Q13 0 (0%) 0 (0%) 5 (100%)
Q14 0 (0%) 1 (20%) 4 (80%)
Q15 1 (20%) 0 (0%) 4 (80%)
Based on the literature criteria, questions with scores 
lower than 0.80 or represented in the tables by 80% were 
excluded. In the case of the topic Signs and Symptoms a 
Q1, Q5, Q8, Q10, Q12. Thus, of the 15 questions only 5 
were discarded, representing 33.3% of questions. 
Although Q14 and Q15 reached an average 
of 80%, they were excluded based on the specialists’ 
(semantic analysis) assignments that the instrument was 
highly favoring the symptom of hepatic encephalopathy 
and disregarding other symptoms also common in CH. It 
was decided to leave the instrument with fewer questions 
portraying encephalopathy.
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Table 3 - Diagnosis: Questions presentation.
DIAGNOSIS
Q1 Liver cirrhosis is a disease that attacks the liver
Q2
Hepatic cirrhosis can be caused by different causes, 
for example, hepatitis, alcohol and autoimmune 
diseases, among other causes
Q3 Liver cirrhosis is a disease that affects the elderly due to weakened liver function
Q4 The diagnosis of liver cirrhosis does not require a change in eating habits
Q5 Liver cirrhosis is considered a serious disease and if left untreated can lead to death
Q6 Liver cirrhosis allows moderate consumption of alcohol
Q7 Liver biopsy is one of the tests used for the diagnosis of liver cirrhosis
Q8
The diagnosis of liver cirrhosis forbids the practice of 
physical exercises as they may impair the functioning 
of the liver
Q9 The only cause of liver cirrhosis is excessive alcohol consumption
Q10 Liver cirrhosis is a contagious disease
Q11 Liver cirrhosis is considered a chronic disease, ie it will accompany the individual throughout life
Q12 The sick liver in liver cirrhosis may impair the functioning of other organs
Q13
The diagnosis of liver cirrhosis makes continuous 
medical follow-up essential for early detection of 
possible complications of the disease
Q14 Hepatic cirrhosis is caused by the exaggeration of hot beverages ingested daily
Q15 Hepatocarcinoma (liver cancer) is a disease that may be present along with the diagnosis of liver cirrhosis
These 15 questions were submitted to the same 
analysis showed in Table 2, where based on the evaluation 
of the specialists, the instrument in the diagnosis topic 
presented 16% of responses considered confusing (12/75), 
21.3% of responses considered unclear (16/75) and 62.7% 
of answers considered clear. (47/75).  
Questions with scores of less than 80% were 
excluded for the topic Diagnostic Q3, Q4, Q5 Q7, Q8, 
Q12, Q14. Therefore, of the 15 questions 7 were discarded, 
representing 46.6% of questions.
Table 4 - Treatment: Questions presentation      
TREATMENT
Q1 In cases of severe cirrhosis, the only form of treatment is transplantation
Q2 Transplantation is characterized by the exchange of one sick liver for another healthy one
Q3 Transplantation is considered a low complexity surgery
Q4
Some foods can harm the patient with liver cirrhosis 
and need to be avoided, so it is necessary to follow 
up with a nutritionist
Q5
When diagnosing liver cirrhosis, it is necessary to 
organize with a social support network to assist 
with hospital visits, medication use and care during 
treatment
Q6
When entering the transplant list it is necessary to 
continue in multiprofessional follow-up (nursing, 
nutrition, psychology, social work)
Q7
The transplant list works according to the order of 
arrival, that is, patients enrolled by first receive the 
organ before the second, and thus consecutively
Q8
Rejection of the new organ may occur after 
transplantation, and this means the possibility of a 
retransplantation
Q9
When entering the transplant queue, a waiting period 
begins for the organ. This period can be quite stressful, 
leading to symptoms of anxiety and depression that 
must be followed by psychiatrists and psychologists
Q10 After the transplant, no medical follow-up or hospital will be necessary because the disease will be cured
Q11 Life habits (work, physical activities and feeding) need to be adapted after transplantation
Q12
To receive the appropriate care, after the transplant 
surgery the patient goes to the ICU and later to the 
infirmary
Q13
The MELD of the patient is one of the criteria 
for allocation in the transplant queue (result of an 
examination)
Q14 Once enrolled in the transplant queue it can no longer be removed
Q15 A high MELD value indicates a greater severity of the disease
Table 4 was submitted to the evaluation of the 
specialists, the instrument in the topic Treatment received 
the following answers: 16% were considered confusing 
(12/75), 16% considered unclear (12/75), and 68% 
considered clear (51/75).
Questions with scores lower than 80% were 
excluded for the topic Treatment Q1, Q3, Q7, Q8, Q11, 
Q13 Q14. Therefore, of the 15 questions 7 were discarded, 
representing 46.6% of questions. Q15 changed to the 
diagnostic topic.
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Table 5 - Medication: Questions presentation
MEDICATION
Q1 Continued use of medications may cause other (negative) 
health effects
Q2 Medications used to treat liver cirrhosis cause sexual impotence
Q3 The medications prescribed by the doctor are exaggerated 
and cause undesirable side effects
Q4 Lactulone is one of the main medicines used in the treatment of hepatic encephalopathy
Q5
The medications prescribed by the doctor are not for 
curing cirrhosis but for treating and controlling the 
symptoms of the disease
Q6
Before taking any medication it is essential to talk to the 
doctor because some medicines should be avoided by 
further damaging the sick liver
Q7 Drug treatment can cure liver cirrhosis and no longer require transplantation
Q8
It is important that the medicines are ingested according 
to the medical orientation, following the exact dosage 
and times
Q9 After transplantation, I must use the medication (immunosuppressive drugs) for the rest of my life
Q10
Immunosuppressive drugs lower the body’s immunity 
which leads to a greater likelihood of acquiring other 
diseases (for example, colds), so it is necessary to take 
greater care with health
Q11
The transplant aims to cure liver disease, which means 
that after it is done it will no longer be necessary to use 
any medication
Q12
It is possible to stay without taking the immunosuppressive 
drugs for a maximum of one week without causing 
damage to the new transplanted organ
Q13
When presenting an undesirable side effect of 
immunosuppressants I must inform the doctor before 
taking any medication
Q14
Immunosuppressive drugs are very expensive, which 
makes it difficult to use them according to medical 
orientation
Q15
Adherence to drug treatment can be facilitated with 
family support, which can assist with timing and correct 
use of the drug, for example.
Table 5 - In the topic Medications the expert 
evaluation presented 10.7% of answers considered 
confusing (8/75), 17.3% of responses considered unclear 
(13/75) and 72% of responses considered clear (54/75).. 
Questions with scores below 80% were excluded 
for the topic Medications Q1, Q3, Q4, Q6, Q7, Q10, 
Q14. Therefore, of the 15 questions 7 were discarded, 
representing 46.6% of questions. 
Q12 and Q13 were discarded despite having 
obtained an average of 80%, the justification for excluding 
these questions is related to a repetition of this content - 
immunosuppressive drugs on several questions. Given that 
the proposal is also to make the instrument less extensive 
and put the topic medication as a subcategory of the 
treatment.
The next step was related to the semantic and 
content analysis performed by the evaluators. Based on the 
various comments of the semantic analysis, the suggested 
changes were made and the questions were restructured. 
The semantic analysis of the evaluators presented 
almost unanimously the suggestion to change the word 
hepatic cirrhosis to cirrhosis in the liver. From a general 
perspective it can be observed that the experts put as 
suggestions to make use of a simpler and accessible 
language to the target audience. The scores were relevant 
and accepted in the restructuring of the instrument for the 
2nd version.  
Suggestions for subjects or contents that were not 
addressed in the first version of the instrument and that 
were considered relevant by the experts in each topic will 
be presented below.
Table 6 – General comments on topics: suggestion or addition 
of content
Topics Relevant contents to be addressed
Signs and 
Symptons
Alert to the stool darkening symptom;
Address the symptom of esophageal varices;
Presence of memory problems, tiredness 
and depressive symptoms;
E n c e p h a l o p a t h y  w i t h  d r o w s i n e s s , 
forgetfulness, aggressive behavior.
Diagnosis
Obesity as a cause associated with cirrhosis;
Diagnosis performed in the decompensated 
phase;
Aspects of illness for being silent;
Importance of early diagnosis.
Treatment
Take focus only from transplantation as 
a treatment, including other possibilities 
of treatment, medicinal, nutritional, 
psychological;
Differentiated care requiring the pre- and 
post-transplantation;
Relevance of follow-up during treatment to 
monitor symptoms;
Address need for support network, family, 
spouse.
Medications Address different actions of medications, preventive, improvement of symptoms, etc.
An analysis of the contents suggested by the 
specialists was carried out. (in bold in the table above) have 
become questions in the second version of the instrument. 
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The very specific contents suggested within the topics 
were discarded in the production and restructuring of the 
questions, since it was understood that contemplating very 
specific questions could make the instrument very long and 
the objective would be to lose a broad view of the patient’s 
knowledge. 
Second version of the instrument
The second version of the instrument had 46 
questions, distributed in the topics signs and symptoms, 
diagnosis, treatment and subcategory medicines.
Evaluation of psychometric properties
Each category presents 10 questions + 6 questions 
of the subcategory medication. A total of 50 responses were 
obtained by category and 30 responses for the medication 
subcategory.
The tables, with the questions and the result of the 
evaluation of the specialists are shown below.
Table 7 – 2nd version – Signs and symptons: questions presentation 
with CVI
SIGNS AND SYMPTONS CVI
Q1 Cirrhosis of the liver (hepatic) can cause malnutrition and leave the patient weak 60
Q2
Body itching, yellowing of the skin, watery belly, 
mental confusion (hepatic encephalopathy), 
esophageal varices are some symptoms of cirrhosis 
in the liver (hepatic)
100
Q3 Having no symptoms means that cirrhosis in the liver (liver) is not in a severe stage 100
Q4
The belly of water (ascites) is a common complication 
of cirrhosis in the liver (hepatic) and is characterized 
by the accumulation of fluid in the belly
100
Q5 Esophageal varices are rare complications in cirrhosis of the liver (hepatic) 80
Q6
Cirrhosis of the liver (hepatic), in some cases, 
presents complications (esophageal varices, mental 
confusion, belly of water) that must be treated and 
accompanied by the doctor to avoid worsening of 
the state of health
100
Q7
The symptom of fatigue is not a complication of 
cirrhosis in the liver (hepatic), fatigue is caused by 
severe depression
100
Q8
Hepatic encephalopathy presents as signs: mental 
confusion, disorientation, tremors in the hands, 
slurred speech, slow movements, loss of memory, 
and in more severe cases can lead to coma
100
Q9
The liver with liver cirrhosis releases toxic 
substances that can attack the heart and cause 
cardiac arrest
100
Q10
Patients who present hepatic encephalopathy attacks 
as signs of mental confusion, disorientation, slow 
movements, etc. should always go out accompanied
80
In the modification the Q3 have a worsening of the 
CVI. The other questions were the same.
Table 8  – 2nd version - Diagnosis: questions presentation with CVI
DIAGNOSIS CVI
Q1 Cirrhosis of the liver is characterized by liver damage that causes the organ to lose its functions 100
Q2 The only cause of cirrhosis in the liver (liver) is alcohol consumption 60
Q3 It is possible to have cirrhosis in the liver (liver) and hepatocarcinoma (liver cancer) at the same time 100
Q4 Liver cirrhosis (hepatic) disease requires continuous medical follow-up to assess the path of the disease 100
Q5
Cirrhosis of the liver (liver) can be caused by different 
causes, for example: hepatitis B or C, alcohol, liver fat 
and autoimmune diseases
100
Q6 Cirrhosis of the liver (hepatic) is a contagious disease transmitted by the bite of a mosquito 80
Q7
Liver cirrhosis is often discovered when the patient 
has complications of the disease: watery belly, mental 
confusion (encephalopathy), varicose veins of the 
esophagus, yellowing of the skin
100
Q8 Liver cirrhosis (hepatic) allows moderate alcohol consumption 100
Q9 Liver cirrhosis is considered a chronic disease, ie it will accompany the individual throughout life 100
Q10 A high MELD value indicates a greater severity of the disease 80
We observed that in the second CVI there was a 
worsening in Q2, and despite the worsening the question 
was maintained. There was an improvement in Q1, Q6, 
Q9 and Q10. The other questions were the same.
Table 9 - 2nd version – Treatment: questions presentation
TREATMENT CVI
Q1 The treatment of cirrhosis in the liver (hepatic) requires only medical monitoring 80
Q2
When transplantation is indicated as a treatment for 
cirrhosis in the liver (lhepatic), it is necessary to follow 
the professionals (doctors, nurses, psychologists, 
nutritionists, social workers) both in the pre-transplant 
period and in the post-transplant period.
80
Q3
Nutritionists’ dietary guidelines are not indicated in the 
treatment of cirrhosis in the liver (hepatic), as no food 
can aggravate symptoms and illness
100
Q4 Liver transplantation is surgery in which the sick liver (with cirrhosis) is replaced by a healthy liver 100
Q5
When entering the liver (hepatic) transplant queue it is 
necessary to undergo evaluations and follow up with 
several professionals, such as nurses, nutritionists, 
psychologists, social workers, etc.
100
Q6
The treatment of cirrhosis in the liver requires a social 
support network, ie help from friends and / or family 
members for hospital visits, medication use and tasks 
of daily living
100
Q7
After enrollment in the liver (hepatic) transplant queue, 
waiting for the organ can be stressful, in this period it 
may arise from symptoms of anxiety and depression 
that need to be followed up by psychiatrists and 
psychologists
80
Q8
In order to receive adequate care after transplant 
surgery in the liver (hepatic) the patient stays an 
interned period in the ward, and only in severe cases 
or complications can he go to the ICU
100
Q9
After recovery from liver (liver) transplant surgery no 
further medical follow-up is needed considering that 
the disease has been cured
80
Q10
The patient may have different emotional reactions 
(fears, anxieties, sadness, restlessness) during the 
treatment of cirrhosis in the liver (liver), in the period 
before and after transplantation.
80
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In the modification there was worsening of the Q8 
and in Q5, Q6, and Q9 there was an improvement. The 
other questions were the same.
Table 10 - 2nd version - Medications: questions presentation
MEDICATIONS CVI
Q1 Medications used to treat liver cirrhosis (hepatic) cause sexual impotence 80
Q2
The medicines are not to cure cirrhosis in the 
liver (lhepatic) but to control the symptoms of 
the disease
100
Q3
It is important that medications are taken 
according to medical advice, following dosages 
and times
100
Q4
The goal of the transplant is to cure cirrhosis of 
the liver, which means that after it is done it will 
no longer be necessary to use any medication
100
Q5
Adherence to drug treatment can be facilitated 
with family support, which can assist with timing 
and correct use of the drug, for example.
100
Q6
After transplantation I should use the medication 
against rejection (immunosuppressive drugs) for 
the rest of my life
100
Qualitative analysis of the instrument
In the second version of the instrument, spaces were 
left for specialists to suggestions and comments on the 
semantic analysis of the questions. It should be noted that 
only added questions had spaces for writing. 
The experts have not made any semantic 
consideration that has been judged the second round of 
evaluation of the instrument changes in the questions. Thus, 
in this qualitative analysis, there are no results. 
Quantitative analysis of the instrument
This second analysis was added only in the second 
version of the instrument. The objective was to evaluate 
some specific criteria of the instrument, if the text was: 
clear, objective, adapting to the context, the Brazilian 
culture and the evaluated population.
 The results were analyzed through the CVI, 
maintaining the standard of the literature acceptance 
criterion equal to or greater than 80. In the instrument need 
to have at least 4 of 5 specialists responding on the likert 
4 or 5 scale to accepted. 
All questions were adequate in all criteria, except 
for Q3 of “signs and symptons” in clear category and 
treatment’s Q1   in adapting to the context.
CONCLUSIONS 
The development of the instrument followed the 
steps described in literature. Each question put forward 
went through an extensive evaluation process and the 
suggestion of the evaluators allowed to restructure the 
questions making them clearer and more relevant to the 
proposal of the instrument. Qualitative and quantitative 
analyzes were performed, following the suggested 
psychometric standards for content validity, which made 
the instrument adequate and reliable. 
Based on the objectives of this study, it can be said 
that it was possible to achieve satisfactorily the proposal 
of the construction of the instrument. 
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